FORMULATION, DEVELOPMENT AND

OPTIMIZATION OF PROPRANOLOL FDDS

SUSTAINED RELEASE AS AN ANTI-
HYPERTENSIVE

PRESENTORS:
Ayesha Saeed 30 M
Fatima Usman 23M
Ramisha Ali 34M
Arsalan Siddique 27M
Ibrar Baig 11M
 TABLE OF CONTENTS
1 2 3 4 5

Results
Methods (Post formulation)
Introduction Results
to FDDS (Preformulation) Conclusion
 PROPRANOLOL

Enhanced bioavailability

Introduction to
FDDS Better absorption characteristics

Sustained drug delivery

Reduced frequency of dosing

Protection from pH
PROPANEX 20 mg
 Mixing of ingredients, drug polymer
1 and disintegrants

Preparation of wet mass by adding

2 binder solution

Methods
Passing wet mass through seive to
3 form granules

4 Drying Granules

5 Seiving of dried granules

6 Mixing of lubricant and glidant

 Pre-Formulation Studies

Formulations Optimized
Hardness Tester
Bulk density 0.4

Results Tapped density 0.51

Carr's Index 22.9

Dissolution Apparatus
Hausner's Ratio 1.37

Angle of repose 34.5

Hardness 5.2
M.P: 163-164 °C
Bulk & Tapped density
Floating Lag time >12
 Dissolution Time
Post-Formulation Studies
Hours FS5
0.5 0.035
Parameter Optimized
1 0.064

k0 9.768 1.5 0.078

2 0.099
Rsqr 0.7279
3 0.121
AIC 78.4184 4 0.167

Results MSC 1.1015

6
8
0.189
0.214
10 0.248
k1 0.223 12 0.275
Rsqr 0.9798
Release Kinetics
AIC 52.3941
MSC 3.7039
kH 28.096
Rsqr 0.9845
AIC 49.7487
MSC 3.9685
kKP 25.288
n 0.555
Rsqr 0.9914
AIC 45.9102
MSC 4.3523
 Aims & Objectives

• To reduce the dosing frequency of propranolol tablets.

• To enhance gastric retention time
• To increase bioavailability of drug
• To get sustained release effect from a single dose administration
Goals :
• Propranolol Tablet seems to be floating/Buoyant which causes slow
Conclusion release of drug
• F5 Formulation contains effervescent excipients which causes
effervescene .
• The formulations prepared showed good results for this system of
Propranolol the best being F5 formulation provided excellent results
and is optimized.
 • Salve V, Mishra R, Nandgude T, Development and optimization
of a floating multiparticulate drug delivery system for
Norfloxacin, Turkish journal of pharmaceutical sciences 2019.
• Kumar S, Keerthy H.S, Yadav R.P, Role of floating tablet in oral
drug delivery system, Asian journal of pharmaceutical
research and development. 2021
• Chaturvedi, K., Umadevi, S., & Vaghani, S. (2010). Floating
matrix dosage form for propranolol hydrochloride based on
References gas formation technique: development and in vitro evaluation.
Scientia pharmaceutica, 78(4), 927-940.
• Gökbulut, E., Vural, İ., Aşıkoğlu, M., & Özdemir, N. (2019).
Floating drug delivery system of itraconazole: Formulation, in
vitro and in vivo studies. Journal of Drug Delivery Science and
Technology, 49, 491-501.
• Kalam, M. N., Rasool, M. F., Rehman, A. U., & Ahmed, N.
(2020). Clinical pharmacokinetics of propranolol
hydrochloride: a review. Current Drug Metabolism, 21(2), 89-
105